Literature DB >> 1973941

Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors.

F D Yocca1.   

Abstract

Preclinical neurochemical studies indicate that buspirone and gepirone bind selectively to presynaptic (dorsal raphe) and postsynaptic (hippocampus, cortex) 5-hydroxytryptamine1A (5-HT1A) receptor binding sites. Furthermore, in functional neurochemical and electrophysiologic receptor studies, azapirones in general display partial agonist activity at postsynaptic 5-HT1A receptors linked negatively to adenyl cyclase and appear to demonstrate a similar profile on hippocampal CA1 pyramidal neurons sensitive to the effects of 5-HT. Through their action at presynaptic 5-HT1A receptors, these agents have been shown to dose-dependently inhibit cortical and hippocampal 5-HT synthesis while inhibiting the firing of 5-HT--containing dorsal raphe neurons, both in vitro and in vivo. These results suggest that the efficacy seen in clinical trials of anxiety and depression may be related to buspirone's and gepirone's complex interaction with presynaptic and postsynaptic 5-HT1A receptors, which initiate long-term changes in central 5-HT neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973941     DOI: 10.1097/00004714-199006001-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

1.  Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells.

Authors:  H W Boddeke; A Fargin; J R Raymond; P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

2.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

3.  A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.

Authors:  David H Overstreet; Darin J Knapp; Sheryl S Moy; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2003-04-04       Impact factor: 4.530

Review 4.  5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Authors:  Alvaro L Garcia-Garcia; Adrian Newman-Tancredi; E David Leonardo
Journal:  Psychopharmacology (Berl)       Date:  2013-12-12       Impact factor: 4.530

Review 5.  5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Authors:  J E Barrett; K E Vanover
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Intravenous buspirone for the prevention of postoperative nausea and vomiting.

Authors:  Peter Kranke; Kerstin D Röhm; Pierre Diemunsch; Tong J Gan; Christian C Apfel; Leopold Eberhart; Harold S Minkowitz; Jan Wallenborn; Dominique Chassard; Gilles Lebuffe; Gabriel M Fox; Martin R Tramèr
Journal:  Eur J Clin Pharmacol       Date:  2012-05-01       Impact factor: 2.953

7.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.

Authors:  Kari Laine; Outi Ahokoski; Risto Huupponen; Jutta Hänninen; Sanna Palovaara; Jori Ruuskanen; Harry Björklund; Markku Anttila; Juha Rouru
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

8.  Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam.

Authors:  J B Richards; K E Sabol; T H Hand; D C Jolly; G J Marek; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

9.  Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.

Authors:  D E Selley; M L Banks; C M Diester; A M Jali; L P Legakis; E J Santos; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2020-12-22       Impact factor: 4.030

10.  Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.